T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.86B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.49B |
| 3 |
Broadcom
AVGO
|
+$1.29B |
| 4 |
Sempra
SRE
|
+$1.26B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PayPal
PYPL
|
+$1.66B |
| 2 |
HCA Healthcare
HCA
|
+$1.02B |
| 3 |
BNY
Bank of New York Mellon
BNY
|
+$949M |
| 4 |
American Tower
AMT
|
+$931M |
| 5 |
FRC
First Republic Bank
FRC
|
+$890M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.29% |
| 2 | Technology | 17.01% |
| 3 | Financials | 16.32% |
| 4 | Consumer Discretionary | 14.01% |
| 5 | Industrials | 10.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KW
1351
DELISTED
Kennedy-Wilson Holdings
KW
| $9.23M | ﹤0.01% |
531,735
-213,105
| -29% | -$4.01M |
|
1352
Copa Holdings
CPA
$6.14B
| $9.14M | ﹤0.01% |
68,157
-1,704
| -2% | -$222K |
|
1353
CytomX Therapeutics
CTMX
$760M
| $9.08M | ﹤0.01% |
430,087
+120,004
| +39% | +$2.49M |
|
1354
Ichor Holdings
ICHR
$2.67B
| $8.94M | ﹤0.01% |
+363,571
| New | +$10.3M |
|
|
CETV
1355
DELISTED
Central European Media Enterprises Ltd
CETV
| $8.89M | ﹤0.01% |
1,912,126
+430,526
| +29% | +$1.97M |
|
1356
Rhythm Pharmaceuticals
RYTM
$7.99B
| $8.84M | ﹤0.01% |
+304,127
| New | +$8.04M |
|
|
GXP
1357
DELISTED
Great Plains Energy Incorporated
GXP
| $8.7M | ﹤0.01% |
269,817
+67,334
| +33% | +$2.21M |
|
1358
Regenxbio
RGNX
$704M
| $8.48M | ﹤0.01% |
+255,067
| New | +$7.68M |
|
|
ASRT
1359
DELISTED
Assertio
ASRT
| $8.47M | ﹤0.01% |
17,545
+3,265
| +23% | +$1.27M |
|
1360
Synaptics
SYNA
$4.3B
| $8.4M | ﹤0.01% |
210,416
-335,382
| -61% | -$12.8M |
|
|
LJPC
1361
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $8.4M | ﹤0.01% |
260,969
-46,910
| -15% | -$1.53M |
|
1362
Sally Beauty Holdings
SBH
$1.55B
| $8.28M | ﹤0.01% |
441,595
+1,062
| +0.2% | +$18.4K |
|
1363
Ternium
TX
$10.8B
| $8.27M | ﹤0.01% |
+261,672
| New | +$7.83M |
|
1364
Forte Biosciences
FBRX
$1.57B
| $8.26M | ﹤0.01% |
2,148
+191
| +10% | +$762K |
|
|
FBMS
1365
DELISTED
The First Bancshares, Inc.
FBMS
| $8.23M | ﹤0.01% |
+240,794
| New | +$7.68M |
|
|
MXIM
1366
DELISTED
Maxim Integrated Products
MXIM
| $8.22M | ﹤0.01% |
157,177
-10,090
| -6% | -$524K |
|
|
CRZO
1367
DELISTED
Carrizo Oil & Gas Inc
CRZO
| $8.19M | ﹤0.01% |
384,744
-23,671
| -6% | -$437K |
|
1368
Coherus Oncology
CHRS
$176M
| $8.09M | ﹤0.01% |
919,202
-292,270
| -24% | -$3.13M |
|
1369
Polaris
PII
$3.9B
| $8.03M | ﹤0.01% |
64,783
-4,822
| -7% | -$572K |
|
1370
Markel Group
MKL
$22.8B
| $7.88M | ﹤0.01% |
6,916
-488
| -7% | -$533K |
|
1371
James River Group Holdings
JRVR
$199M
| $7.82M | ﹤0.01% |
+195,501
| New | +$7.93M |
|
1372
Genpact
G
$5.78B
| $7.8M | ﹤0.01% |
245,654
-17,650
| -7% | -$547K |
|
1373
CALL
Synchrony
SYF
$26.1B
| $7.72M | ﹤0.01% |
200,000
| – | – |
|
1374
Olin
OLN
$2.13B
| $7.69M | ﹤0.01% |
216,065
-12,132
| -5% | -$431K |
|
|
DISCK
1375
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $7.66M | ﹤0.01% |
361,870
+23,300
| +7% | +$429K |
|
Similar funds
T. Rowe Price Associates's Q4 2017 Portfolio in Review
As of Q4 2017, T. Rowe Price Associates held 2,692 positions worth $616B, up 5.3% from $585B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
T. Rowe Price Associates's Q4 2017 filing shows 121 new, 947 increased, 1,282 reduced and 130 closed positions. Its largest new stake was CarGurus: 13,060,603 shares worth $374M. The largest sale was PayPal, an estimated $1.66B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 18% a quarter earlier, followed by Technology and Financials.
- T. Rowe Price Associates's largest Q4 2017 buy was CarGurus: 13,060,603 shares worth $374M.
- T. Rowe Price Associates added most to Tesla in Q4 2017, an estimated $1.86B increase.
- T. Rowe Price Associates's biggest Q4 2017 reduction was PayPal, cutting an estimated $1.66B.
- T. Rowe Price Associates fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $483M.
- T. Rowe Price Associates's ten largest holdings make up 19% of its $616B portfolio in Q4 2017.
- T. Rowe Price Associates opened 121 new positions and closed 130 in Q4 2017.
- T. Rowe Price Associates's portfolio value rose 5.3% quarter-over-quarter to $616B.
Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.